Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ODD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: ODD. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-001471-37 Sponsor Protocol Number: B4Z-SB-LYDW Start Date*: 2006-10-31
    Sponsor Name:Lilly Deutschland GmbH, Teichweg 3, 35396 Gießen
    Full Title: A Randomized, Double-Blind Comparison of Atomoxetine versus Placebo in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
    Medical condition: Children and adolescents with ADHD (Attention-Deficit/Hyperactivity Disorder) and comorbid ODD (Oppositional Defiant Disorder).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001916-37 Sponsor Protocol Number: MATRICS_WP6-1 Start Date*: Information not available in EudraCT
    Sponsor Name:RADBOUD UNIVERSITY MEDICAL CENTER
    Full Title: The neuropsychological characterization of aggressive behaviour in children and adolescents with Conduct Disorder or Oppositional Defiant Disorder (CD/ODD)
    Medical condition: Aggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10037183 Psychic disturbance LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002474-13 Sponsor Protocol Number: 3.199 Start Date*: 2017-04-24
    Sponsor Name:Innovatiefonds Zorgverzekeraars
    Full Title: Medication Optimization for ADHD: MOVA study Implementation and evaluation of double-blind placebo-controlled titration in clinical practice
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000567-26 Sponsor Protocol Number: 2010-021883-14 Start Date*: 2013-01-31
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents.
    Medical condition: Conduct Disorder DSM-IV-TR; 312.8x¸ APA, 2000
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064478 Conduct disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002207-13 Sponsor Protocol Number: NRA1280023 Start Date*: 2006-06-29
    Sponsor Name:Dept. Child & Adolescent Psychiatry Univ. Freiburg
    Full Title: Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial
    Medical condition: conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003407-34 Sponsor Protocol Number: pre-CIN Start Date*: 2021-06-01
    Sponsor Name:Oslo University Hospital
    Full Title: A randomized clinical three-arm trial comparing inflammation and cystoid macular edema for the medication regimens preoperative and postoperative topical NSAIDs to only postoperative topical NSAIDs...
    Medical condition: Cataract surgery, and the medical treatment is anti-inflammatory eye drops to treat (and prevent) intraocular inflammation and development og cystoid macular edema.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002002-20 Sponsor Protocol Number: 2014METAL1 Start Date*: 2015-06-10
    Sponsor Name:UMCG
    Full Title: A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate
    Medical condition: attention-deficit/hyperactivity disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019930-28 Sponsor Protocol Number: 31116 Start Date*: 2011-03-09
    Sponsor Name:Accare
    Full Title: The effectiveness of Parent-Child Interaction Therapy versus methylphenidate in preschool children with ADHD and disruptive behavior problems with insufficient improvement through Parent Management...
    Medical condition: ADHD ODD
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064104 ADHD LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021884-34 Sponsor Protocol Number: PERS3 Start Date*: 2013-01-24
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: Relapse prevention in children and adolescents with DSM-IV Conduct Disorder treated with Risperidone: a Randomized Double blind, Placebo-Controlled, Discontinuation Study.
    Medical condition: Conduct Disorder DSM-IV-TR; 312.8x, APA 2000
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064478 Conduct disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005514-10 Sponsor Protocol Number: 0822-018 Start Date*: 2012-03-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduc...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001863-21 Sponsor Protocol Number: FIOL Start Date*: 2018-08-14
    Sponsor Name:Vestre Viken Hospital Trust
    Full Title: First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies.
    Medical condition: Lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) LT (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005663-34 Sponsor Protocol Number: EC20081 Start Date*: 2009-06-26
    Sponsor Name:Joseba Andoni Santamaría Zuazua
    Full Title: Ensayo clínico sobre la eficacia de una pauta con amoxicilina/clavulánico 2000/125 mg (GE) cada doce horas, frente a placebo(GC) en la prevención de la infeccion postoperatoria tras la exodoncia de...
    Medical condition: prevención de la infección postoperatorioa tras la exodoncia de terceros molares totalmente incluidos recubiertos por hueso mandibular
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002236-32 Sponsor Protocol Number: IMCgp100-401 Start Date*: 2016-11-22
    Sponsor Name:Immunocore Limited
    Full Title: An Open-label, Multi-Center, Rollover Study in Patients with Advanced Melanoma After Completing an IMCgp100 Clinical Study
    Medical condition: Advanced Melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025667 Malignant melanoma site/stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005490-30 Sponsor Protocol Number: PP21/14 Start Date*: 2022-04-28
    Sponsor Name:Hospital Universitario Son Llàtzer
    Full Title: EFFECTIVENESS OF TREATMENT WITH ANTISEPTICS VERSUS TOPICAL ANTIBIOTICS IN MILD IMPETIGO IN PEDIATRIC PATIENTS
    Medical condition: Impetigo is a bacterial infection of very common skin in the pediatric population. In the usual clinical practice, the treatment of this infection has been based on topical antibiotics. The widespr...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003408-15 Sponsor Protocol Number: DMEC Start Date*: 2021-06-14
    Sponsor Name:Oslo University Hospital
    Full Title: A randomized clinical two-arm trial comparing inflammation and cystoid macular edema for the medication regimens postoperative topical NSAIDs and steroids to only postoperative topical steroids in ...
    Medical condition: Corneal disease/opacification treated with corneal endothelial transplantation (DSAEK or DMEK surgery), and the medical treatment is anti-inflammatory eye drops to treat (and prevent) intraocular i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002971-12 Sponsor Protocol Number: IMCgp100-201 Start Date*: 2016-05-26
    Sponsor Name:Immunocore Limited
    Full Title: A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compa...
    Medical condition: Advanced Malignant Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001829-26 Sponsor Protocol Number: ECU-NMO-303 Start Date*: 2019-12-18
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10077879 Neuromyelitis optica spectrum disorder relapse LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000441-41 Sponsor Protocol Number: NB-ND021(NM21-1480)-101 Start Date*: 2021-10-26
    Sponsor Name:Numab Therapeutics AG
    Full Title: A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004390-41 Sponsor Protocol Number: BLU-667-1101 Start Date*: 2018-03-13
    Sponsor Name:Blueprint Medicines
    Full Title: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
    Medical condition: Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10066914 Thyroid tumor LLT
    20.0 100000004864 10025044 Lung cancer LLT
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001353-96 Sponsor Protocol Number: BMBF-ADHD-C2 Start Date*: 2006-12-20
    Sponsor Name:Universitätsklinikum Würzburg
    Full Title: Wirksamkeit eines Elterntrainings zur Behandlung der Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) bei Kindern in Abhängigkeit von der Behandlung ihrer ebenfalls betroffenen Mütter mit ...
    Medical condition: Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) bei Kindern und Erwachsenen (Mütter der Kinder) Mit einer Prävalenz von 3-6% ist die ADHS eine der häufigsten psychischen Störungen im Kin...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003736 Attention deficit/hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 13:47:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA